hard capsules
Sponsors
Hospices Civils De Lyon, Noema Pharma AG, Fundacio Privada Mon Clinic Barcelona, Biogen Idec Research Limited, Region Hovedstaden
Conditions
AsthmaChronic Obstructive Pulmonary DiseaseFriedreich’s ataxiaTourette Syndromeparkinson's disease
Phase 2
Phase 3
A Phase 3, 2-Part, Randomized, Double-Blind, Placebo-Controlled Study (Part 1) and Open-Label Extension (Part 2) to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich’s Ataxia Aged 2 to < 16 Years
RecruitingCTIS2025-520896-13-00
Start: 2025-12-04Target: 127Updated: 2025-12-08
Evaluating the effect of inhaled levodopa (Inbrija®) for early morning off in Parkinson’s disease
Not yet recruitingCTIS2026-526465-18-00
Target: 22Updated: 2026-06-25
Phase 4
Symptoms control and adhErenCe assessment during treatment with mepolizUmab new pREfilled devices. SECURE
CompletedCTIS2022-501029-19-00
Start: 2022-12-13End: 2025-03-27Target: 130Updated: 2024-01-15
THE ANTES B+ STUDY: AN OPEN-LABEL, PRAGMATIC, RANDOMIZED, CONTROLLED TRIAL OF TRIPLE THERAPY VERSUS LABA-LAMA COMBINATION TO IMPROVE CLINICAL CONTROL IN HIGH-RISK GOLD B PATIENTS (B+)
CompletedCTIS2023-507304-32-00
Start: 2024-02-09End: 2025-01-23Target: 1028Updated: 2024-04-04